Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders (females and males) over 18 years of age~* Written informed consent obtained from the subjects prior to any procedures related to the study~* Understand all procedures to be applied within the scope of the study protocol~* Ambulatory patients with symptoms diagnosed with COVID-19 with Chest tomography (CT) result positivity in the last 72 hours~* Patients with stable clinical course and who could be treated on an ambulatory basis.~Exclusion Criteria:~* Patients who has partial oxygen saturation below 93% and require immediate hospitalisation after diagnosis~* Patients, upon initial examination, decided to be hospitalised at the intensive care-unit~* Inability or unwillingness to give written informed consent~* At physicians decision, the trial involvement will not be in patients' best interest, or any condition that does not allow the protocol to be followed safely~* Patients considered as inappropriate for this study for any reason~* Active participation in another clinical study~* Uncontrolled Type 1 or type 2 diabetes~* Severe liver disease (e.g. Child Pugh score ≥ C, AST\>5 times upper limit)~* Patients with known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis~* Significant cardiovascular co-morbidity (i.e. heart failure)~* Patients with phenylketonuria (contraindicated for NAC)~* Known allergy for substances used in the study~* Pregnant or breastfeeding patients, or patients with positive pregnancy test in a pre-dose examination~* Receipt of any experimental treatment for COVID-19 within the 30 days prior to the time of the screening evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Subjects in ambulatory-at home-treatment will receive hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Subjects will take hydroxychloroquine (standard therapy) + dietary supplement placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).